These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7626852)

  • 21. Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer.
    Luciani A; Bertuzzi C; Ascione G; Di Gennaro E; Bozzoni S; Zonato S; Ferrari D; Foa P
    Lung Cancer; 2009 Oct; 66(1):94-6. PubMed ID: 19171407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-dense chemotherapy for primary breast cancer.
    Kümmel S; Rezai M; Kimmig R; Schmid P
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolving concepts in the systemic drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New approaches to adjuvant chemotherapy for breast cancer.
    Hudis C
    Pharmacotherapy; 1996; 16(3 Pt 2):88S-93S. PubMed ID: 8726587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute in vivo resistance in high-dose therapy.
    Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
    Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of the application of response surface methodology in the combination therapy of cancer.
    Carter WH; Wampler GL
    Cancer Treat Rep; 1986 Jan; 70(1):133-40. PubMed ID: 3943113
    [No Abstract]   [Full Text] [Related]  

  • 29. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Dose factors/time factors in chemotherapy].
    Philip T; Bouffet E; Biron P; Brunat-Mentigny M
    Bull Cancer; 1989; 76(9):979-94. PubMed ID: 2695186
    [No Abstract]   [Full Text] [Related]  

  • 31. Adjuvant chemotherapy--clinical trials and laboratory models.
    Wittes RE
    Cancer Treat Rep; 1986 Jan; 70(1):87-103. PubMed ID: 3510738
    [No Abstract]   [Full Text] [Related]  

  • 32. Rationale for the use of alternating non-cross-resistant chemotherapy.
    Goldie JH; Coldman AJ; Gudauskas GA
    Cancer Treat Rep; 1982 Mar; 66(3):439-49. PubMed ID: 7060033
    [No Abstract]   [Full Text] [Related]  

  • 33. Relative dose intensity: improving cancer treatment and outcomes.
    Lenhart C
    Oncol Nurs Forum; 2005 Jul; 32(4):757-64. PubMed ID: 15990905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical concepts derived from animal chemotherapy studies.
    Goldin A; Schabel FM
    Cancer Treat Rep; 1981; 65 Suppl 3():11-9. PubMed ID: 7049366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The importance of dose intensity in the outcome of chemotherapy.
    Hryniuk WM
    Important Adv Oncol; 1988; ():121-41. PubMed ID: 3042601
    [No Abstract]   [Full Text] [Related]  

  • 36. Safer cancer chemotherapy using a kinetically-based experimental approach: higher dose intensity with reduced toxicity.
    Price LA
    Cancer Treat Rev; 1987 Dec; 14(3-4):215-23. PubMed ID: 3440249
    [No Abstract]   [Full Text] [Related]  

  • 37. New experimental approaches to reducing carcinogenicity in animals by modifying regimens.
    Habs M; Schmähl D
    IARC Sci Publ; 1986; (78):177-85. PubMed ID: 3108155
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of dose-intense chemotherapy on the development of permanent drug resistance.
    Coldman AJ; Goldie JH
    Semin Oncol; 1987 Dec; 14(4 Suppl 4):29-33. PubMed ID: 3686044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug dosage intensity--a panel discussion.
    McGuire WL; Goldie J; Hryniuk W; Tormey DC
    Breast Cancer Res Treat; 1987; 9(2):87-100. PubMed ID: 3620720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Optimal posology in the neoplastic treatment (author's transl)].
    Periti P
    Radiol Med; 1981; 67(7-8):537-49. PubMed ID: 7335926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.